Plain-English translation of NCT06158139 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new kind of cancer treatment called iC9-CAR.B7-H3 T cells, which are your own immune cells taken from your blood and modified in a lab to better recognize and attack pancreatic cancer. The modified cells are designed to find cancer cells and destroy them, while also containing a safety feature that allows doctors to turn them off if needed. This is an early-stage study to see if this treatment is safe and how well it works for people whose pancreatic cancer has not responded to other treatments.
Pancreatic cancer is very difficult to treat, and many patients develop resistance to standard chemotherapy. This trial exists because researchers believe that harnessing your own immune system in this new way might offer hope for people whose cancer has stopped responding to conventional treatments.
You likely qualify if…
You likely don't qualify if…
You will have blood drawn so doctors can collect and modify your immune cells in the laboratory over several weeks. Once the cells are ready, you'll receive an infusion of the modified cells as an inpatient, and the study team will carefully monitor you for safety. You'll have follow-up visits to check how you're responding and watch for any side effects. This is a phase 1 trial, meaning it's focused on safety, so close medical supervision and frequent check-ins are an important part of your involvement.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
United States